These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors. Erkinjuntti T; Román G; Gauthier S J Neurol Sci; 2004 Nov; 226(1-2):63-6. PubMed ID: 15537522 [TBL] [Abstract][Full Text] [Related]
6. Galantamine in the treatment of vascular dementia. Brashear HR Int Psychogeriatr; 2003; 15 Suppl 1():187-93. PubMed ID: 16191239 [TBL] [Abstract][Full Text] [Related]
7. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl). Maelicke A Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923 [TBL] [Abstract][Full Text] [Related]
8. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Kurz AF; Erkinjuntti T; Small GW; Lilienfeld S; Damaraju CR Eur J Neurol; 2003 Nov; 10(6):633-40. PubMed ID: 14641507 [TBL] [Abstract][Full Text] [Related]
9. Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors. Erkinjuntti T; Román G; Gauthier S Neurol Res; 2004 Jul; 26(5):603-5. PubMed ID: 15265282 [TBL] [Abstract][Full Text] [Related]
10. Treatment options: the latest evidence with galantamine (Reminyl). Erkinjuntti T J Neurol Sci; 2002 Nov; 203-204():125-30. PubMed ID: 12417370 [TBL] [Abstract][Full Text] [Related]
11. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Corey-Bloom J Int J Clin Pract; 2003 Apr; 57(3):219-23. PubMed ID: 12723727 [TBL] [Abstract][Full Text] [Related]
12. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. Small G; Erkinjuntti T; Kurz A; Lilienfeld S CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529 [TBL] [Abstract][Full Text] [Related]
13. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV; Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497 [TBL] [Abstract][Full Text] [Related]
14. [The use of galantamine in Alzheimer's disease associated with vascular dementia (according to the study of T. Erkinjuntti group)]. Damulin IV Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5):65-7. PubMed ID: 19938276 [No Abstract] [Full Text] [Related]
15. Use of galantamine to treat vascular dementia. Moretti R; Torre P; Antonello RM; Cazzato G; Bava A Lancet; 2002 Nov; 360(9344):1512-3; author reply 1513. PubMed ID: 12433549 [No Abstract] [Full Text] [Related]
16. Use of galantamine to treat vascular dementia. van Gool WA Lancet; 2002 Nov; 360(9344):1512; author reply 1513. PubMed ID: 12433548 [No Abstract] [Full Text] [Related]
17. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Harry RD; Zakzanis KK Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322 [TBL] [Abstract][Full Text] [Related]
19. Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Farlow MR Mayo Clin Proc; 2006 Oct; 81(10):1350-8. PubMed ID: 17036561 [TBL] [Abstract][Full Text] [Related]
20. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. Rockwood K; Fay S; Gorman M Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]